OTC Markets · Healthcare
Aditxt stock from India: price, numbers and tax
Aditxt (ADTX) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Aditxt at a glance
- Price
- $0.00+$0.00 (33.33%)
- Market cap
- $399.19K
- Day range
- $0.00 – $0.00
- P/E
- -0.00
- Dividend yield
- None
- Volume
- 33.17K
- 1 month
- -87.50%
- 6 months
- -99.99%
- YTD
- -100.00%
- 1 year
- -100.00%
- 5 years
- -100.00%
Aditxt statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $3.2K | $134.0K | $645.2K | $933.7K | $105.0K |
| Gross profit | $268.0 | −$493.0K | −$111.7K | $166.9K | $27.1K |
| Operating income | −$19.6M | −$27.9M | −$26.1M | −$25.5M | −$41.9M |
| Net income | −$41.7M | −$34.4M | −$32.4M | −$27.6M | −$46.4M |
| Earnings per share | −$1,153.83 | −$3,062.42 | $0.00 | $0.00 | $0.00 |
| EBITDA | −$40.1M | −$27.0M | −$25.5M | −$24.8M | −$44.0M |
| Total assets | $16.5M | $32.1M | $44.6M | $10.7M | $16.7M |
| Total debt | $3.0M | $6.9M | $18.2M | $3.4M | $4.7M |
| Cash and short-term investments | $3.2M | $833.0M | $97.1K | $2.8M | $7.9M |
| Shareholders' equity | $5.6M | $8.9M | $16.1M | $5.2M | $10.2M |
| Operating cash flow | −$25.7B | −$16.8M | −$18.6M | −$22.4M | −$22.3M |
| Free cash flow | −$25.7B | −$16.8M | −$18.6M | −$22.8M | −$23.3M |
| Capital expenditure | −$13.7M | $1.0 | −$14.4K | −$367.1K | −$1.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Adlai Nortye | ANL | $9.65 | $511.96M |
| Tharimmune | THAR | $3.54 | $139.94M |
| Apollomics | APLM | $21.36 | $62.26M |
| Athira Pharma | ATHA | $6.75 | $26.62M |
| Citius Pharmaceuticals | CTXR | $0.56 | $15.50M |
| BioLineRx | BLRX | $1.87 | $9.05M |
| Moleculin Biotech | MBRX | $8.33 | $8.49M |
| SeaStar Medical | ICU | $2.07 | $5.86M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $1,280.00
- High
- $1,280.00
- Median
- $1,280.00
- Consensus
- $1,280.00
Ratings: 1 buy · 1 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
Why invest in Aditxt from India
What Aditxt does
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Aditxt shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Aditxt shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.